HALO Halozyme Therapeutics Inc
Price (delayed)
$57.75
Market cap
$7.11B
P/E Ratio
16.5
Dividend/share
N/A
EPS
$3.5
Enterprise value
$8.5B
Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in
Highlights
HALO's EPS has surged by 64% year-on-year and by 14% since the previous quarter
HALO's net income has surged by 58% year-on-year and by 13% since the previous quarter
Halozyme Therapeutics's quick ratio has increased by 28% YoY but it has decreased by 26% from the previous quarter
The company's equity fell by 20% QoQ
Key stats
What are the main financial stats of HALO
Market
Valuations
Earnings
Shares outstanding
123.15M
Market cap
$7.11B
Enterprise value
$8.5B
Price to earnings (P/E)
16.5
Price to book (P/B)
20.19
Price to sales (P/S)
7.21
EV/EBIT
14.78
EV/EBITDA
12.95
EV/Sales
8.37
Revenue
$1.02B
Gross profit
$855.91M
Operating income
$551.48M
Net income
$444.09M
EBIT
$575.23M
EBITDA
$656.54M
Free cash flow
$468.37M
Per share
Balance sheet
Liquidity
EPS
$3.5
EPS diluted
$3.43
Free cash flow per share
$3.69
Book value per share
$2.86
Revenue per share
$8.01
TBVPS
$9.82
Total assets
$2.06B
Total liabilities
$1.7B
Debt
$1.51B
Equity
$363.82M
Working capital
$946.24M
Debt to equity
4.14
Current ratio
7.8
Quick ratio
6.5
Net debt/EBITDA
2.12
Margins
Efficiency
Dividend
EBITDA margin
64.7%
Gross margin
84.3%
Net margin
43.7%
Operating margin
54.3%
Return on assets
22.2%
Return on equity
138.4%
Return on invested capital
24.2%
Return on capital employed
29.9%
Return on sales
56.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HALO stock price
How has the Halozyme Therapeutics stock price performed over time
Intraday
0.54%
1 week
-0.93%
1 month
3.24%
1 year
50.55%
YTD
20.79%
QTD
20.79%
Financial performance
How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$1.02B
Gross profit
$855.91M
Operating income
$551.48M
Net income
$444.09M
Gross margin
84.3%
Net margin
43.7%
The company's operating income has surged by 63% YoY and by 16% QoQ
HALO's net income has surged by 58% year-on-year and by 13% since the previous quarter
HALO's gross profit is up by 34% YoY and by 10% QoQ
The operating margin is up by 33% year-on-year and by 8% since the previous quarter
Growth
What is Halozyme Therapeutics's growth rate over time
Valuation
What is Halozyme Therapeutics stock price valuation
P/E
16.5
P/B
20.19
P/S
7.21
EV/EBIT
14.78
EV/EBITDA
12.95
EV/Sales
8.37
HALO's EPS has surged by 64% year-on-year and by 14% since the previous quarter
The stock's price to earnings (P/E) is 44% less than its 5-year quarterly average of 29.5 and 4.1% less than its last 4 quarters average of 17.2
HALO's price to book (P/B) is 47% lower than its 5-year quarterly average of 37.8 and 4.8% lower than its last 4 quarters average of 21.2
The company's equity fell by 20% QoQ
The price to sales (P/S) is 38% lower than the 5-year quarterly average of 11.6 but 6% higher than the last 4 quarters average of 6.8
The company's revenue rose by 22% YoY and by 7% QoQ
Efficiency
How efficient is Halozyme Therapeutics business performance
Halozyme Therapeutics's return on assets has increased by 41% YoY and by 8% QoQ
HALO's return on invested capital is up by 37% year-on-year and by 11% since the previous quarter
The ROE has contracted by 32% YoY and by 12% from the previous quarter
HALO's return on sales is up by 28% year-on-year and by 8% since the previous quarter
Dividends
What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HALO.
Financial health
How did Halozyme Therapeutics financials performed over time
The company's total assets is 21% higher than its total liabilities
Halozyme Therapeutics's quick ratio has increased by 28% YoY but it has decreased by 26% from the previous quarter
The company's current ratio fell by 25% QoQ but it rose by 17% YoY
Halozyme Therapeutics's debt to equity has plunged by 77% YoY but it has increased by 25% from the previous quarter
The company's equity fell by 20% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.